CalciMedica, Inc. (CALC)
| Market Cap | 15.80M -69.3% |
| Revenue (ttm) | n/a |
| Net Income | -19.54M |
| EPS | -1.27 |
| Shares Out | 15.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 514,826 |
| Open | 0.860 |
| Previous Close | 0.840 |
| Day's Range | 0.848 - 1.000 |
| 52-Week Range | 0.461 - 7.200 |
| Beta | 1.20 |
| Analysts | Strong Buy |
| Price Target | 10.50 (+950.0%) |
| Earnings Date | Aug 10, 2026 |
About CALC
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumati... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for CALC stock is "Strong Buy." The 12-month stock price target is $10.5, which is an increase of 950.00% from the latest price.
News
CalciMedica announces FDA alignment on Phase 2b Auxora trial design
CalciMedica (CALC) announced that, following a Type C Focused Meeting, the U.S. Food and Drug Administration and the company have aligned on Phase 2b trial endpoints and a patient population…
CalciMedica, FDA alignment de-risks regulatory path, says H.C. Wainwright
FDA alignment on CalciMedica’s (CALC) acute pancreatitis program for Auxora de-risks the regulatory path, validating Phase 2b endpoint selection and patient enrichment strategy while advancing a poten...
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
FDA aligned on new-onset severe respiratory failure as the Phase 2b primary endpoint, with multi-organ failure and time to medically indicated discharge as key secondary endpoints FDA aligned on a str...
CalciMedica files to sell 56.02M shares of common stock for holders
16:13 EDT CalciMedica (CALC) files to sell 56.02M shares of common stock for holders
CalciMedica Registration statement: Registration filing
CalciMedica filed a registration statement on July 24, 2026, providing details about a securities offering with the SEC.
CalciMedica Proxy statement: Proxy filing
CalciMedica filed a proxy statement on July 23, 2026, providing details for shareholder voting and corporate governance matters.
CalciMedica Proxy statement: Proxy filing
CalciMedica filed a proxy statement on July 13, 2026, providing details for shareholder voting and corporate governance matters.
CalciMedica announces $49M private placement
CalciMedica (CALC) announced it has entered into a definitive securities purchase agreement with leading healthcare investors for a private placement for up to approximately $49M in gross proceeds. Th...
CalciMedica announces FDA review of protocol amendment for Kourage trial
CalciMedica (CALC) announced that the FDA has reviewed a protocol amendment and interim safety data for CalciMedica’s Phase 2 KOURAGE trial in patients with Stage 2 or Stage 3 acute…
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral C...
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora in AKI patients No comments or questions were received Confirms CalciMedica's ability to continue cli...
CalciMedica Quarterly report: Q1 2026
CalciMedica has published its Q1 2026 quarterly earnings report on May 12, 2026.
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 Preclinical and IND-enabling studies advancing for CM5480,...
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™ D esign of pivo...
CalciMedica Registration statement: Registration Filing
CalciMedica filed a registration statement on March 3, 2026, providing details about a securities offering with the SEC.
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
Safety concern warrants reevaluation of study design, including enrollment criteria Potential future trial with Auxora™ in AKI to be evaluated after data analysis LA JOLLA, Calif., Jan. 28, 2026 /PRNe...
CalciMedica Registration statement: Registration Filing
CalciMedica filed a registration statement on November 13, 2025, providing details about a securities offering with the SEC.
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026 Positive discussions with FDA on pivotal trial in acute pancreati...
CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension
Preclinical data support CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiated therapy for pulmonary arterial hypertension (PAH), both as monotherapy and in combination with ex...
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
Treatment with Auxora significantly reduced IL-17–related inflammation in both kidney and lung, significantly increased glomerular filtration rate (GFR), and decreased renal injury in a rat model of A...
CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™
AI tools will allow CalciMedica to analyze Phase 2 datasets to refine the target patient populations and efficacy endpoints for upcoming pivotal trials LA JOLLA, Calif. , Oct. 14, 2025 /PRNewswire/ --...
CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
LA JOLLA, Calif. , Sept. 2, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium releas...
CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in early 2026 Productive initial meeting with the FDA on Auxora in acute pa...
CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
LA JOLLA, Calif. , July 8, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release...
CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure
Publication includes previously announced preclinical data of Auxora™ in acute kidney injury (AKI) models as well as a post-hoc analysis of patients in the Phase 2 CARDEA trial of Auxora in severe COV...